Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The management of congenital adrenal hyperplasia due to 21-hydroxylase (CYP21) deficiency requires glucocorticoid substitution with oral hydrocortisone given twice or thrice daily. In paediatric practice little is known of the bioavailability of oral hydrocortisone tablets used in these patients. The aim of this study was to assess the bioavailability of oral hydrocortisone and to evaluate current replacement therapy in the light of cortisol pharmacokinetic properties. We determined the bioavailability of hydrocortisone following oral and intravenous administration in sixteen (median age: 10.9 years, range: 6.0-18.4 years) adequately controlled CYP21 deficient patients. Serum total cortisol concentrations were measured at 20-min intervals for 24 h while patients were on oral substitution therapy, and at 10-min intervals for 6 h following an intravenous bolus of hydrocortisone in a dose of 15 mg/m(2) body surface area. The area under the serum total cortisol concentration versus time curve (AUC) following oral and intravenous administration of hydrocortisone was calculated using the trapezoid method. The bioavailability was estimated by dividing the corrected for dose AUC after oral hydrocortisone administration by the corrected for dose AUC after the intravenous hydrocortisone administration and was exemplified as a percentage. After oral administration of hydrocortisone in the morning, median serum total cortisol concentrations reached a peak of 729.5 nmol/l (range: 492-2520 nmol/l) at 1.2 h (range: 0.3-3.3 h) and declined monoexponentially thereafter to reach undetectable concentrations 7 h (range: 5-12 h) after administration. Following administration of the evening hydrocortisone dose, median peak cortisol concentration of 499 nmol/l (range: 333-736 nmol/l) was attained also at 1.2 h (range: 0.3-3.0 h) and subsequently declined gradually, reaching undetectable concentrations at 9 h (5-12 h) after administration of the oral dose. After the intravenous hydrocortisone bolus a median peak serum total cortisol concentration of 1930 nmol/l (range: 1124-2700 nmol/l) was observed at 10 min (range: 10-20 min). Serum cortisol concentrations fell rapidly and reached undetectable levels 6 h after the hydrocortisone bolus. The absolute bioavailability of oral hydrocortisone in the morning was 94.2% (90% confidence interval (CI): 82.8-105.5%) whereas the apparent bioavailability in the evening was estimated to be 128.0% (90% CI: 119.0-138.0%). We conclude that the bioavailability of oral hydrocortisone is high and may result in supraphysiological cortisol concentrations within 1-2 h after administration of high doses. The even higher bioavailability in the evening, estimated using as reference the data derived from the intravenous administration of hydrocortisone bolus in the morning, is likely to reflect a decrease in the hydrocortisone clearance in the evening. Decisions on the schedule and frequency of administration in patients with congenital adrenal hyperplasia should be based on the knowledge of the bioavailability and other pharmacokinetic parameters of the hydrocortisone formulations currently available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schuirmann, D. J. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01068419 · Cited by 2,696
Bioavailability of Hydrocortisone From Commercial 20-mg Tablets
Patel, R. B., Rogge, M. C., Selen, A., Goehl, T. J., Shah, V. P., Prasad, V. K., & Welling, P. G. (1984) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600730726 · Cited by 20 · cited 2×
“This variation in bioavailability was thought to be due to incomplete absorption secondary to intrinsic absorption effects, first-pass clearance at the liver, or both (Patel et al. 1984).”
BackgroundMethod
Cited by
Charmandari, E., Nicolaides, N. C., & Chrousos, G. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61684-0 · Cited by 644
Self-citationHafezi-Moghadam, A., Simoncini, T., Yang, Z., Limbourg, F. P., Plumier, J.-C., Rebsamen, M. C., Hsieh, C.-M., Chui, D.-S., Thomas, K. L., Prorock, A. J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-473 · Cited by 594
Mortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Adrenal insufficiency: still a cause of morbidity and death in childhood
Shulman, D. I., Palmert, M. R., Kemp, S. F., & for the Lawson Wilkins Drug and Therapeutics Committee (2007) · PEDIATRICS · doi:10.1542/peds.2006-1612 · Cited by 282
Mah, P. M., Jenkins, R. C., Rostami‐Hodjegan, A., Newell‐Price, J., Doane, A., Ibbotson, V., Tucker, G. T., & Ross, R. J. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02106.x · Cited by 243
“Animal studies have suggested CBG levels peak at around 18·00 h (Hsu & Kuhn, 1988), and it has been suggested that an evening dose of HC may have delayed clearance (Charmandari et al., 2001).”
BackgroundInfluential
Metadata
- Authors
- Charmandari, E., Johnston, A., Brook, C., & Hindmarsh, P.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2001-04-01
- Volume
- 169
- Issue
- 1
- Pages
- 65-70
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W1985839768
- Cited by
- 104
- References
- 2
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. https://app.cochat.ai/papers/10.1677/joe.0.1690065
- The paper
- Charmandari, E., Johnston, A., Brook, C., & Hindmarsh, P. (2001). Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Endocrinology. https://doi.org/10.1677/joe.0.1690065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.